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1. Introduction 
Ochratoxin A (OTA) is a well-known mycotoxin produced by species of Aspergillus and 
Penicillium genera, mainly A. ochraceus and P. verrucosum. It can contaminate a great variety 
of vegetal products, especially grains, and enter the food chain through several commodities. 
OTA is considered nephrotoxic, hepatotoxic, immunosuppressive, neurotoxic, and teratogenic 
(EFSA, 2006). However, the main concern regarding OTA toxicity is its carcinogenic potential. 
The International Agency for Research on Cancer classified OTA as a possible human 
carcinogen (group 2B) (IARC, 1993), the National Toxicology Program 14th Report on 
Carcinogens as reasonably anticipated to be a human carcinogen (NTP, 2016), and Lock and 
Hard (2004) regarded this xenobiotic as one of the most potent renal carcinogens in rodents. 
However, significant sex and species differences in kidney sensitivity have been described: 
male rodents are more sensitive than females and rats are considerably more sensitive than mice 
(EFSA, 2006). Unfortunately, relatively little information is available to allow an understanding 
of the mechanisms that underlay these differences, and also, few short-term toxicity studies 
have been carried out in rats of both sexes. 
Based on the organ- and site-specificity of OTA effect, ochratoxin uptake by kidney transporters 
has been proposed as a key event in the mode of action of the mycotoxin. Indeed, this event has 
been suggested to explain some of the sex- and species- differences in sensitivity towards OTA 
(EFSA, 2006, Mally, 2012). 
 Several studies have demonstrated that OTA can be transported by Slc22 (Oat), Abc, Slco1 
(Oatp) and Slc15 (Pept) protein families (for a review, Anzai et al., 2010), and interestingly, 
most of them show species-, organ- or/and sex-dependent expression. Sabolic et al., (2007) 
reviewed gender differences in kidney function, especially, expression of transporters in rats. In 
general, despite some variation between studies, Oat1, Oat3, Mrp2, Mrp4, Bcrp and Oatp1 show 
higher expression in males, while Oat2, Oat5 and Pept2 are more expressed in female rats. On 
the other hand, some toxicogenomic studies have shown a clear downregulation of some 
transporters, mainly Oat1, Oatp1 and Mrp2, after OTA exposure in male rats treated for 7 or 21 
days with 0.30 or 0.50 mg/kg bw (body weight) (Arbillaga et al., 2008, Marin-Kuan et al., 
2006). Moreover, a dual effect has been observed in Oat transporters expression depending on 
the dose in male Wistar rats treated every 2nd day for 10 days: upregulation at low doses (25, 50 
µg/kg bw) and downregulation at high dose (500 µg/kg bw) (Zlender et al., 2009). In addition, 
after a single administration of 0.50 mg/kg bw, a sex- and time-dependent profile was observed 
in some transporters. The most prominent change affected Oat2 expression that was upregulated 
in males and downregulated in females after 48h (Pastor et al., 2016). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Several studies have demonstrated that hormones affect transporters expression, which might 
explain some sex differences previously described. The expression of Oat1, Oat3 and Oatp1 was 
increased by testosterone and inhibited by estrogens (Kudo et al., 2002, Ljubojevic et al., 2004, 
Lu et al., 1996). In contrast, estrogens enhanced Oat2 and Oat5 expression, whilst testosterone 
decreased their expression (Breljak et al., 2010, Kudo et al., 2002, Ljubojevic et al., 2007). On 
the other hand, progesterone increased Oat1, Oat2 and Oat5 expression, did not affect Oat3 and 
diminished Bcrp and Pept1 (Breljak et al., 2010, Ljubojevic et al., 2004, Ljubojevic et al., 2007, 
Watanabe et al., 2006, Wu et al., 2013). Besides sex hormones, Pept1 and Pept2 expression was 
shown to be decreased due to thyroid regulation (tri-iodothyronine, T3, and thyroxine, T4) (Lu 
and Klaassen, 2006). On the other hand, some studies have demonstrated that OTA could 
interfere with hormone production (Frizzell et al., 2013, Gharbi et al., 1993, Hassan et al., 2010, 
Kumar et al., 2011, Mor et al., 2014, Woo et al., 2013). However, OTA-induced effect is 
uncertain because different models (in vitro or in vivo), doses or time of exposure have been 
used.  
Thus, to gain further insight into the molecular mechanisms of the early stage of OTA renal 
toxicity, the aim of the present study was to evaluate the sex-dependent response of F344 rats 
after a repeated OTA oral administration for 7 (0.50 mg/kg bw) or 21 days (0.21 and 0.50 
mg/kg bw). For that purpose, general toxicity, urine and biochemistry parameters and 
histopathology of both target (kidney) and non-target (liver) organs were evaluated. OTA was 
quantified in plasma, kidney and liver samples by high-performance liquid chromatography - 
fluorescence detection (HPLC-FLD), in order to correlate its levels with the lesions found. 
Moreover, the expression of the main transporters was studied in kidneys, by real-time 
quantitative reverse transcription polymerase chain reaction (RT-qPCR), for a better 
understanding of their role in mycotoxin accumulation after repeated administration, as well as 
their possible expression change due to both OTA or/and hormone regulation. And finally, sex 
and thyroid hormones have been quantified for evaluating their possible impact in the final 
outcomes regarding histopathological lesions and transporters regulation. 
2. Materials and methods  
2.1 Chemicals 
Ochratoxin A was obtained in powder from Sigma-Aldrich (Steinheim, Germany). It was 
dissolved in sodium bicarbonate (NaHCO3 0.1M pH 7.4) (Sigma-Aldrich Steinheim, Germany) 
for animal treatment and in methanol HPLC grade (Sigma-Aldrich Steinheim, Germany) for 
HPLC analysis stock solutions. Then, it was aliquoted and maintained at -20 °C until use.  
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All reagents used for the HPLC analysis were of pro-analysis grade. Absolute ethanol, 
trichloroacetic acid 20%, sodium acetate anhydrous (CH3COONa), ortho-phosphoric acid (85%) 
and sodium hydroxide (NaOH) were purchased from Panreac (Barcelona, Spain). Acetonitrile 
and methanol HPLC grade were obtained from Sigma-Aldrich (Steinheim, Germany). Sodium 
dihydrogen phosphate monohydrate (NaH2PO4*1H2O) was obtained from Merck (Darmstadt, 
Germany). Normal saline solution (NaCl 0.9%) was obtained from Braun Medical SA 
(Barcelona, Spain). Type I water (Ultramatic Type I, Wasserlab Navarra, Spain) was used to 
prepare all aqueous solutions. The aqueous phases were filtered through a 0.45 µm nylon 
membrane filter (Teknokroma, Barcelona, Spain). Samples were filtered before injection into 
HPLC with low protein binding Durapore® (polyvinylidene difluoride, PVDF) 0.45 µm 
membrane filter from Millex®-HV (Merk Millipore Cork, Ireland).  
2.2 Safety precautions  
Due to its toxicity, OTA has always been handled in solution, thereby avoiding the formation of 
dust and aerosols. Nitrile gloves and FFP3 masks were used for all procedures carried out and 
during the manipulation of treated animals or contaminated samples. 
2.3 Animals 
This study was approved by the Ethics Committee on Animal Experimentation of the University 
of Navarra. All animals were supplied by Charles Rivers Laboratories (France). Eleven-weeks 
old male and female Fisher 344 (F344/IcoCrl) rats of 260.93 ± 12.0 and 157.98 ± 8.52 g, 
respectively on day of arrival (table 1 supplementary data), were used for the repeated oral dose 
study.  At the commencement of the study the weight variation of the animals did not exceed ± 
20% of the mean weight of each sex, as recommended by OECD guidelines (OECD, 2008).  
Females were not synchronized for estrous cycle. Moreover, twelve-week old male F344 rats 
(275.27 ± 7.48 g on day of arrival) were used for obtaining biological samples for HPLC-FLD 
method revalidation. All animals were used after a week of acclimatization, housed in 
polycarbonate cages with stainless steel covers, under standard conditions (temperature 22 ± 3 
°C, humidity 50 ± 20%, 12h light/dark cycle) and provided with sterile food (Harlan) and water 
ad libitum.  
2.4 Treatment and study design 
Animals (n= 60) were randomly distributed into ten groups of 6 animals (5 groups of males and 
5 groups of females). Following a week of acclimatization, animals were daily gavaged 
(maximum volume of 1 mL/0.1 kg bw) with their corresponding treatment for 7 or 21 days. In 
one hand, two groups of each sex were treated for 7 days respectively with the vehicle 
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(NaHCO3 0.1 M pH 7.4) (control group), or with 0.50 mg of OTA/kg bw (high dose group). On 
the other hand, three groups per sex were administered for 21 days: control, low dose (0.21 mg 
of OTA/kg bw) and high dose (0.50 mg of OTA/kg bw). Rats were daily weighted for adjusted 
administration while food and water consumption were measured once a week. For urine 
collection, rats were transferred into metabolic cages 12 h prior to necropsy without food but 
with free access to drinking water. After 24h of the last administration, animals were euthanized 
by decapitation. Unfortunately, two rats should be euthanized for ethical reasons while the study 
was carried out. For that reason, at the end of the 21 days study, male control and female low 
dose groups had 5 animals instead of 6.  
Urine volume was measured and an aliquot was immediately used for biochemical analysis. The 
remaining urine was aliquoted and stored at -40 °C for future studies. 
Blood from decapitation was collected into heparinized tubes (BD Vacutainer system, K3E 5.4 
mg Plus Blood Collection Tubes Plymouth, UK) and centrifuged (1085 ×g for 15 min at 4 °C) 
in order to obtain plasma for biochemical analysis and OTA quantification. For hormones 
quantification, blood was collected into serum separator gel tubes (Venosafe™, Terumo® La 
Rioja, Spain), allowed to clot for 20 min and centrifuged (695 ×g for 10 min at room 
temperature) for serum obtention. Both, plasma and serum samples, were stored at -20 °C until 
analysis. 
Heart, spleen, liver, adrenal glands, kidneys, testes or ovaries and thymus were removed and 
weighted. Brain and lungs were removed and flash frozen in liquid nitrogen. For this study, 
right kidneys were cleaned with water, until external blood was removed, and then cut 
longitudinally. One half of right kidney, a piece of liver, and all other organs were fixed in 
formaldehyde 3.7-4.0% w/v buffered to pH 7 and stabilized with methanol (Panreac Barcelona, 
Spain) for histological evaluation. The other kidney half and a piece of liver, were also cleaned 
with water, weighted and flash frozen in liquid nitrogen for HPLC-FLD OTA quantification. 
The reasons for only cleaning with water externally and not flushing by syringe the pieces of 
organs intended for HPLC-FLD analysis were: a) to mimic the conditions of the toxicity studies 
as recommended in the ICH guideline S3A and b) to reproduce previous studies of our group 
(Vettorazzi et al., 2008; 2011) and others (Li et al., 1997; Han et al 2013). Left kidney and the 
remaining parts of liver were cut into small pieces and flash frozen in liquid nitrogen for nucleic 
acids extractions. All frozen tissues were stored at -80 °C. All the dissection material was 
cleaned with water and rinsed with ethanol after each animal necropsy in order to prevent 
contamination between samples. 
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2.5 Urine and plasma biochemistry, hormone determination and histopathology 
Fresh urine samples were analyzed using urine test strips (Combur Test® M cobas®, 
Mannheim, Germany) in Cobas U411 analyzer (Roche Diagnostics) for semi-quantitative 
determination of specific gravity, pH, leucocytes, erythrocytes, nitrite, protein, glucose, ketone 
bodies, urobilinogen, bilirubin and blood. 
Plasma biochemical analysis was performed with a Hitachi 911™ (Roche Diagnostics) analyzer 
using standard protocols according to the manufacturer's instructions. Urea, creatinine, total 
protein, albumin, bilirrubin, glucose, cholesterol, aspartate transaminase (AST) and alanine 
transaminase (ALT) were determined. 
Sex [progesterone (ng/mL), estradiol (pg/mL) and testosterone (ng/mL)] hormone concentration 
was measured by a solid-phase competitive chemiluminescent enzyme immunoassay (Immulite 
2000, Siemens Healthcare Diagnostics Inc.). The method has a relevant specificity for 
progesterone with a cross reactivity for androstenedione, corticosterone, 17α-hydroxy-
progesterone and testosterone <0.45%. Moreover, estradiol and testosterone assays presented an 
imprecision within run <10% and <16.3% in each case, and a cross reactivity for many 
hormones and derivates <1.9% for estradiol and <2.0% for testosterone.  
On the other hand, thyroid hormones, T3 and T4 (nmol/L), were measured by an 
electrochemiluminescence immunoassay “ECLIA” with Cobas 601 immunoassay analyzer. The 
assay employs a competitive test principle with polyclonal antibodies specifically directed 
against the hormone. Endogenous hormone (T3 or T4) competes with the added biotinylated T3- 
or T4-derivative for the binding sites on the antibodies labeled with the ruthenium complex. 
Imprecision of the assay was <3.1% for T3 and <1.8% for T4 and analytical specificity for other 
thyroid hormones and derivates was <0.16% and <1.4% in T3 and T4 respectively. 
For the histopathological analysis, kidney and liver sections fixed in 10% neutral buffered 
formalin were dehydrated and embedded in paraffin. Paraffin sections (3 µm) were cut, 
mounted onto glass slides, and dewaxed and stained with hematoxylin and eosin (H&E) for the 
subsequent examination. Histopathological examination was carried out by an animal 
pathologist (J.A García Jalón) following the terminology recommendations of the European 
College of Veterinary Pathologists. 
2.6 HPLC-FLD method revalidation and OTA quantification in plasma, kidney and liver 
samples 
For OTA quantification a previous specifically validated method (Vettorazzi et al., 2008) for rat 
biological samples was revalidated according to the following parameters: linearity, precision 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
and accuracy (within- and between-day variability), selectivity and recovery in plasma, kidney 
and liver samples. The procedure employed for evaluating these validation parameters was the 
same as in the validation process and it is summed-up below. A pool of blank samples obtained 
from eight male F344 rats (13-week-old not treated) was used for preparing calibration samples 
for recovery experiments. 
OTA standard solution (100 mg/L) was obtained after dissolving 5 mg of OTA in 50 mL of 
methanol. The concentration was tested spectrophotometrically at 330 nm (MW= 403.8 ε= 5500 
M-1 cm-1). Different working standard solutions were prepared by dilution in methanol of this 
standard solution. 
Two calibration curves of six points each (ranges of 2-20 and 20-200 µg/L) were performed 
using three replicates of calibrations standards for each point. They were prepared by 
evaporating 200 µL of the corresponding working standard solutions with a centrifugal vacuum 
concentrator (miVac Duo Concentrator, GeneVac Ipswich, Suffolk, UK) for 15 min at 60ºC. 
Then, they were dissolved in 200 µL of a solution 1:5:8 (trichloroacetic 20% - normal saline 
solution - absolute ethanol), similar to supernatants obtained after OTA extraction from real 
samples. Linearity was verified by: correlation coefficient (r2>0.999), relative standard 
deviation (RSD) between response factor (<5%), slope interval (p= 95%) not having to include 
zero. Moreover, three replicate calibration standards at 2, 6, 20, 60 and 200 µg/L were analyzed 
on 1 day (within-day) and on 3 different days (between-day) to study precision and accuracy of 
the linearity. The data was acceptable when accuracy was within ± 10% SE (standard error of 
the mean) and precision (RSD%) was ≤10%. 
Selectivity was verified by comparing the chromatograms obtained from blank samples, blank 
samples spiked with OTA and OTA-treated rat samples. 
For determining the recovery of the method, plasma, kidney and liver samples were fortified 
with known OTA concentrations: 8.4, 56 and 560 µg/L in plasma and 56, 224 and 2240 µg/L in 
kidney and liver. For that purpose, an adequate volume of the corresponding working standard 
solution were evaporated for 15 min at 60 °C using a centrifugal vacuum concentrator and 
dissolved into 250 µL of blank plasma, kidney or liver tissue homogenate (prepared as 
described in next paragraph) by mixing, first for 2 min in vortex and then for 15 min in a 
rotating shaker. Afterwards, OTA was extracted and analyzed. The recovery value (%) was 
calculated by dividing measured concentration by theoretical OTA concentration. OTA could be 
detected, under quantification limit, in blank plasma pool, so this response was subtracted from 
spiked samples areas. Moreover, the repeatability and the reproducibility of the method were 
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studied. Three spiked samples of each concentration were measured on 1 day and on 3 different 
days for each matrix. Recovery values should be within 80-120%. 
Tissue samples preparation was made using thawed pieces of kidney and liver (200-400 mg) 
homogenized for 1 min in a round-bottom plastic tube with 4 µL sodium phosphate buffer (0.05 
M, pH 6.50, adjusted with NaOH) per mg of tissue in a T25 Ultra-turrax Digital High Speed 
Homogenizer (IKA®, Germany). Then, homogenates were aliquoted and stored for at least one 
day at -80 °C until OTA extraction. For that purpose, frozen plasma or tissues homogenates 
were kept at room temperature for 30 min. Then, 400 µL of ice-cold absolute ethanol and 50 µL 
of 20% trichloroacetic acid were added to 250 µL of sample in order to allow protein 
precipitation and OTA release. Then, they were mixed for 2 min using vortex and for 15 min in 
a rotating shaker, and centrifuged (3900 xg for 15 min at 4 °C) for protein precipitation. 
Supernatants were filtered with low protein binding Durapore® (PVDF) 0.45 µm membrane 
filter from Millex®-HV (Merk Millipore) and injected into the HPLC-FLD system. With this 
extraction, plasma and tissues homogenates were diluted 2.8. The final dilution factor for 
kidney and liver samples was 11.2 taking into account the homogenization process and the 
extraction volumes used. Moreover, as high OTA concentration was expected in plasma 
samples from the in vivo study, an additional dilution (1:60) was made with a solution 1:5:8 
(20% trichloroacetic acid - normal saline solution - absolute ethanol). In this case, the final 
dilution factor for plasma was 168.  
HPLC analyses were performed on an Agilent Technologies 1100 liquid chromatographic 
system equipped with a fluorescence detector (model G1321A) controlled by Chemstation 3D 
software. OTA was analyzed on a 5 µm (25 × 0.4 cm) Tracer Extrasil ODS2 column with a 
Tracer Extrasil ODS-2 precolumn, both from Teknokroma (Barcelona, Spain). The mobile 
phase was 29:29:42 (v/v) methanol - acetonitrile - sodium acetate (5 mM acidified to pH 2.6 
with ortho-phosphoric acid) and the flow rate was 1.5 mL/min. The injection volume was 100 
µL. Chromatography was performed at 40 °C and the fluorescence detection conditions were: 
Ex= 225 nm and Em= 461 nm. In these conditions, OTA retention time was 4.5 min. 
2.7 Kidney transporters expression quantification by RT-qPCR 
Gene expression analysis were made using kidney samples obtained from 7 and 21 days control 
and treated (0.50 mg/kg bw/day) rats of both sexes. Transporter families Slc22 (Oat1, Oat2, 
Oat3, Oat5 and Oat8), Abc (Mrp2, Mrp4 and Bcrp), Slco1 (Oatp1 and Oatp2) and Slc15 (Pept1 
and Pept2) were quantified using RT-qPCR as described in Pastor et al. (2016). Briefly, pieces 
of approximatively 50 mg of frozen kidneys were homogenized in TRIzol® (50 mg/mL of 
TRIzol) (Invitrogen™, USA) using a T25 Ultra-turrax Digital High Speed Homogenizer 
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(IKA®, Germany). RNA was isolated according to the TRIzol® manufacturer´s protocol, 
purified using the RNeasy® Mini kit (Qiagen, Hilden, Germany) and finally dissolved in 
RNase-free water. Samples quantity and purity was measured spectrophotometrically 
(SmartSpec™ Plus, Bio-Rad). All samples showed A260/A280 ratio between 1.8 and 2.0. 
Afterwards, they were frozen at -80ºC until DNase treatment was carried out according to 
DNA-free™´s protocol (Ambion® by Life Technologies, USA). For that purpose, 2 µg of RNA 
(volume: 10 µL) were treated with 1 µL of rDNase I plus 1 µL of DNase I Buffer at 37 °C for 
20 min to remove any DNA contamination. Then, cDNA was synthesized following 
manufacturer’s instructions of High Capacity cDNA Reverse Transcription Kit with RNase 
Inhibitor (Applied Biosystems™, USA) in StepOneTM Real-time PCR System (Applied 
Biosystem®, Life Technologies), used as thermocycler. The first strand cDNA synthesis was 
started with random primer annealing at 25 °C for 10 min. Secondly, reverse transcriptase 
reaction (RT) was carried out using MultiScribe™ Reverse Transcriptase for 120 min at 35 °C. 
Finally, the enzymes were inactivated at 85 °C for 5 min. Each reaction was accompanied by a 
no-RT control in which the reverse transcriptase was replaced by RNase free water. cDNA 
samples were stored at -80 °C. 
For RT-qPCR, all plasticware consumables, TaqMan® probe set, as detection and quantification 
method, and TaqMan® Universal PCR Master Mix were obtained from Applied Biosystems™, 
USA. The final PCR reaction mix included 4.5 µL of diluted cDNA sample, 0.5 µL TaqMan® 
“best coverage” gene expression assays for each specific cDNA amplification (Pastor et al., 
2016),  plus 5 µL of TaqMan® Universal PCR Master Mix at a final volume of 10 µL. 
Reactions were performed with the StepOne™ Real-time PCR System following the next 
program: first, a holding stage of 2 min at 50 °C followed by 10 min at 95 °C for DNA 
denaturation and Taq polymerase activation, secondly, the cycling state of 40 cycles for 
amplification at 95°C for 15 s and 60 °C for 1 min. Samples were then cooled to 40 °C for 30 s. 
Sample maximization method (as many samples as possible and one gene analyzed per run) was 
used as the run layout strategy. Each sample was measured in duplicated and inter-run 
calibrators (samples repeated in every run), no-template and no-RT controls were included.  
Ct (threshold cycle) values were obtained and analyzed with StepOne Software v2.2.2 (Applied 
Biosystems™, Life Technologies). Actb, Gapdh, 18S, Ppia and Ubc were evaluated to select the 
best reference gene. Finally, Ppia was chosen as the most stable gene according to different 
approaches [Coefficient of variation (CV), Microsoft Excel NormFinder v0.953 (Andersen et 
al., 2004) and RefFinder (Xie et al., 2011)], and it was used to normalize the expression of 
target genes. Relative mRNA quantification of each target gene was calculated by the 
application of the formula 2-∆∆Ct (∆∆Ct method). First, Ct value was normalized to the reference 
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gene (∆Ct), and then it was quantified according to a calibrator (∆∆Ct), which is the sample used 
in each case as the basis for comparison. 
2.8 Statistical analysis 
Data are presented by descriptive analysis as mean ± standard deviation (SD) of animals. 
However, semi-quantitative urine biochemistry parameters and histopathological findings are 
summed up in frequency tables. Statistical analysis was performed by using software SPSS 
15.0, using Kruskal Wallis H test followed by Mann-Whitney U test. A p-value < 0.05 was 
accepted as the level of significance. 
3. Results 
3.1 General toxicity study 
No clinical signs of toxicity were observed during the study. In addition, OTA treatment did not 
affect food and water consumption (data not shown). However, high dose treated males showed 
a decrease of body weight gain, significant after day 14 of administration (figure 1).  
In order to analyze possible organ weight changes due to mycotoxin administration for 21 days, 
absolute and relative weights of heart, spleen, liver, adrenal glands, kidneys, testes or ovaries 
and thymus were studied (data not shown). In terms of absolute weight, heart, liver and both 
kidneys were smaller than control organs in males and both kidneys and right ovary were 
smaller in treated females than in control ones. But taking into account relative organ weights, 
only a significant dose-dependent increase of testes was observed in males and a light dose-
dependent significant decrease of right kidney was observed in females. 
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Figure 1. Body weight (bw) evolution of F344 rats after a daily oral administration of the vehicle 
(NaHCO3) or OTA (0.21 or 0.50 mg/kg bw) for 21 days. In each sex, treated groups were compared to 
their control. Differences were considered statistically significant (*) when p-value < 0.05 (Mann-
Whitney U test).  
 
Blood biochemistry (table 2 supplementary data) and urianalysis did not show significant 
changes, except in the number of erythrocytes and leucocytes that were found in urine of treated 
rats with respect to control animals (table 1). This effect was more evident in males than in 
females. Moreover, a slightly elevated proteinuria was found in treated males (table 1).  
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Table 1. Presence of erythrocytes, leucocytes and protein in urine of male and female F344 rats 
after a daily oral treatment with vehicle (NaHCO3) or OTA (0.21 or 0.50 mg/kg bw) for 7 and 21 
days. The number of erythrocytes and leucocytes per mL and the protein content in mg/dL is presented 
(in brackets the number of animals with the same value). 
Time (days) 7 21 
Sex Males Females Males Females 
Dose 
(mg/kg) 0 0.50 0 0.50 0 0.21 0.50 0 0.21 0.50 
Animals (n) 6 6 6 5 4 6 6 6 5 6 
Erythrocytes 
(/µL) 
10 (3)   10 (1) 10 (1) 10 (3)           
25 (2)   
 
25 (3) 25 (1) 
 
25 (1) 
 
25 (3) 25 (5) 
  50 (3) 
 
    50 (6) 50 (3) 
 
50 (2) 50 (1) 
  150 (3)   150 (1)     150 (2)       
Leucocytes 
(/µL) 
25 (2)     25 (1) 25 (1)   25 (1)   25 (3) 25 (5) 
100 (3) 100 (2) 
 
100 (2) 100 (3) 100 (4) 100 (1) 
 
100 (1) 100 (1) 
  500 (4)   500 (1)   500 (2) 500 (4)       
Protein 
(mg/dL) 
25 (5) 25 (3) 25 (3) 25 (3) 25 (2) 25 (3) 25 (1) 25 (2) 25 (3) 25 (3) 
75 (1) 75 (3)   150 (1) 75 (2) 75 (3) 75 (4)       
 
Sex (progesterone, testosterone and estradiol) and thyroid (T3 and T4) hormones were measured 
in serum samples. As expected, testosterone in females and estradiol in males, were lower than 
quantification limit. Regarding progesterone levels (figure 2A) a significant dose- and time-
dependent decrease was observed in females. In contrast, although less pronounced, some 21-
day treated males showed a dose-dependent tendency to increase progesterone level (figure 2A). 
No significant changes were observed in testosterone levels in males (figure 2B) or of estradiol 
in females (figure 2C). Finally, our results did not show any changes in T3 and T4 levels after 
OTA treatment (data not shown). 
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Figure 2. Hormone quantification in F344 rats after a daily oral administration of vehicle 
(NaHCO3) or OTA for 7 (0.50 mg/kg bw) or 21 days (0.21 or 0.50 mg/kg bw). A) Individual 
progesterone levels (ng/mL) in males and females. B) Individual testosterone levels (ng/mL) in males. C) 
Estradiol levels (pg/mL) in females. In each sex, treated group was compared to its control. Differences 
were considered statistically significant (*) when p-value < 0.05 or nearly to be significant (t) when p-
value= 0.055 (Mann-Whitney U test). 
 
Liver and kidney tissues of all the animals were analysed. In liver, a very mild increase in the 
number of isolated necrotic cells was observed in treated animals with respect to the controls, 
and this fact was slightly more frequent in males than in females. Also, diffuse inflammatory 
infiltrates were localized both in parenquima and in portal space with a higher frequency in 
animals treated for 21 days than in control and 7-day treated animals, but these differences 
might be not relevant. As can be seen in table 2, the most important findings were concentrated 
in kidneys. In 7-day treated males, a mild or very mild mesangial hyperplasia (figure 3A:a)  was 
detected. This effect was observed in 5/6 males and in none of the females (figure 3A:b). After 
21 days treatment, glomerulonephritis was observed in 6/6 males (figure 3B:a) and 5/5 females 
treated with 0.21 mg/kg bw, and in 3/6 males and 1/6 females treated with 0.50 mg/kg bw. 
Regarding, collecting ducts injury, mild or moderate alterations were observed in almost all the 
treated animals, with slight sexual differences after 7 days of treatment (figure 3A:e and f) but 
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without a clear dose-response effect (table 2). Nevertheless, the most significant findings were 
found in proximal and distal tubules. In all the 7-day treated males and females, proximal tubule 
cells presented degeneration and necrosis (figure 3A: c and d) (table 2). After 21 days, in 
addition to proximal tubulonephrosis, intense alterations of the distal tubules were evident: 
lining cell degeneration could be observed with necrotic and sloughed cells detached in the 
tubule lumen and the presence of karyomegalic cells (figure 3B: c, d, e and f). In particular, 
animals treated with the low dose, showed clear signs of distal tubule cells proliferation (figure 
3B: a and b).  
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Figure 3A. Main degenerative kidney lesions in animals treated with OTA (0.5 mg/kg bw) for 7 
days. a. Mild mesangial hyperplasia of glomeruli and mild degeneration of proximal tubules (arrows) (H. 
E. X 400, male 2). b. Normal glomeruli with mild degeneration of proximal tubules (H. E. X 400, female 
1). c. Severe degeneration and single cell necrosis of proximal tubules (arrows) (H. E. X 400, male 4). d. 
Moderate degeneration of proximal tubules with necrotic cells in the lumen (arrows) (H. E. X 400, female 
3). e. Mild vacuolation in collecting ducts (arrows) (H. E. X 400, male 2). f. Normal collecting ducts (H. 
E. X 400, female 1).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
15 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Figure 3B. Main degenerative kidney lesions in animals treated with OTA (0.21 or 0.5 mg/kg bw) 
for 21 days.  
a. Very mild mesangial hyperplasia of glomeruli, with severe degeneration of proximal tubules (arrow); 
regeneration and karyomegalic cells in distal tubules (arrowhead) (H. E. X 200, male 2). b. Regeneration 
and karyomegalic cells (arrow) in distal tubules (H. E. X 400, female 1). c. Distal tubules with 
karyomegalic cells (arrows) (H. E. X 400, male 1). d. Proximal tubules with single cell necrosis (arrows) 
and distal tubules with karyomegalic cells (arrowhead) (H. E. X 400, female 1). e. Proximal and distal 
tubules degeneration, necrosis (arrows), cell proliferation (arrowhead) and karyomegalic cells (H. E. X 
400, male 2). f. Proximal tubules with single cell necrosis (arrows) and distal tubules with karyomegalic 
cells (arrowhead) (H. E. X 400, female 2). g. Very mild collecting ducts degeneration. (H. E. X 200, male 
1). h. Normal collecting ducts (H. E. X 200, female 1).  
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Table 2. Histopathological findings in kidney samples obtained from male and female F344 rats 
after a daily oral treatment of OTA for 7 (0.50 kg mg/kg bw) or 21 days (0.21 or 0.50 mg/kg bw). 
The lesions found were evaluated based on the following grading system: unobserved or imperceptible (-) 
rare or very little intense or very mild (+) infrequent, less intense, discrete, mild (++) moderately frequent 
or moderate (+++) fairly frequent or severe (++++) very frequent or very intense (+++++). Normal 
histology was observed in control groups kidneys. ID: animal identification. 
 Males Females 
Treatment 
(mg/kg) ID 
Glomerulo-
nephritis 
Tubulo-
nephrosis 
Collecting 
duct 
injury 
Glomerulo-
nephritis 
Tubulo-
nephrosis 
Collecting 
duct 
injury 
7 days 
 
0.50 
1 - ++ +++ - ++ a - 
2 ++ ++ ++ - +++++ - 
3 ++ ++ ++ - +++ + 
4 + ++++ + - + + 
5 + ++++ ++ - + ++ 
6 ++ ++++ + - ++ + 
21 days 
 
0.21 
1 + +++ + + ++++ + 
2 + ++++ + + ++++ + 
3 + ++++ + + ++++ + 
4 + +++++ + + ++++ + 
5 + ++++ +    
6 + ++++ + + ++++ + 
21 days 
 
0.50 
1 - +++ + - ++ 1 - 
2 - ++++ + - ++++ + 
3 - ++++ + - ++++ + 
4 + +++++ + - ++++ + 
5 + ++++ + ++ ++++ + 
6 ++ ++++ + - +++ + 
1
 Steatosis 
3.2 HPLC-FLD method revalidation and OTA quantification in biological samples 
The method was selective in plasma, liver and kidney samples and no interference peaks 
appeared in blank matrices. All the requirements for linearity were verified for the two 
calibration curves generated. Precision and accuracy of the linearity also presented adequate 
values (less than 10%) both within- and between-day (Table 3 supplementary data). Moreover, 
recovery study was made for each matrix (Table 4 supplementary data ), and was very efficient 
(94.14% for plasma 96.79% for kidney and 95.59% for liver) and precise (RSD obtained in 
within- and between-day experiments were below 10%) in all the matrices studied.  
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This analytical procedure was applied to measure plasma, kidney and liver samples of the 
present study and results are presented in figure 4. OTA distribution pattern was the same in all 
the matrices studied. Very high concentrations were measured in plasma, and lower levels were 
found in livers and kidneys. As expected, a higher time of exposure of the same dose and a 
higher dose with the same time of exposure produced significant higher OTA levels in plasma, 
liver and kidney. Thus, the increase of OTA concentration in all the matrices was dose- and 
time-dependent. Regarding sex differences, they are not evident. Comparing both sexes, only 
after 7 days a statistically significant higher plasma and liver concentrations could be detected in 
females compared to males (figure 4). 
  
  
Figure 4. HPLC-FLD OTA quantification in plasma (A), kidney (B) and liver (C) samples obtained 
from male and female F344 rats treated with a daily oral dose of OTA for 7 (0.50 mg/kg bw) or 21 
days (0.21 or 0.50 mg/kg bw). Differences were considered statistically significant when p-value < 0.05 
(Mann-Whitney U test). Within each sex, comparisons were made between the doses (0.21 and 0.50 
mg/kg bw after 21 days) (*), and between the duration of the treatment (7 and 21 days, 0.50 mg/kg bw) 
($). Under each condition, comparisons between both sexes have been studied (#). For comparison with 
other studies, raw data in µg/L or µg/kg as well as on a molar basis can be found in table 5 supplementary 
data.  
3.3 Gene expression analysis by RT-qPCR 
3.3.1 Kidney transporters expression at basal level 
Basal transporters expression was analyzed in all the control animals of this study, in order to 
confirm or discard sex or age related differences under our experimental conditions. To this 
purpose, gene expression of kidney transporters in male and female control animals was studied 
and compared. The results are presented in figure 5. An illustration of the relative expression of 
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each transporter, together with its membrane localization and transport direction is shown in 
figure 7.  
No statistically significant differences were observed in mRNA levels of 15-week-old animals 
(21 days) compared to 13-week-old ones (7 days). 
With respect to sex differences, marked significant differences were observed for some 
transporters at both timepoints. Regarding Slc22 family transporters, Oat2 was much more 
expressed in females than in males. To a lower extent, Oat5 was also more expressed in females 
than in males.  In the Abc family, Bcrp expression was significantly lower in females than in 
males. And in the Slco1 family, Oatp1 was not expressed in females. 
 
 
Figure 5. Kidney transporter basal expression in F344 rats treated with a daily oral dose of vehicle 
(NaHCO3) for 7 or 21 days. 7-day male control rats were used as calibrator group (1 AU mRNA, shown 
as a black line). For each transporter, within each treatment time, comparisons between sexes were 
studied (*). For each transporter, within each sex, comparisons between 7 and 21 days were studied ($). 
Expression changes were considered statistically significant when p-value < 0.05 (Mann-Whitney U test). 
AU: arbitrary units of mRNA level. 
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3.3.2 Kidney transporters expression profiles after 7- and 21-day OTA treatment  
Kidney transporters gene expression was studied in male and female F344 rats administered 
with a daily oral dose (0.50 mg/kg bw) for 7 or 21 days. In order to see if OTA treatment 
induced any change in the expression of these genes, and to determine if this change was sex 
related, and how it was modulated by treatment time, different comparisons were performed. 
Results are presented in figures 6 and 7. 
The most important changes affected Slc22 and Abc families. OTA produced a clear general 
downregulation of Oat transporters in both sexes, with the exception of Oat3, that did not show 
any difference in the mRNA levels in females. Also, comparing both sexes responses after 7 and 
21 days, Oats downregulation was slower in males than in females. Regarding Abc family, after 
21 days, Mpr2 expression increased in both sexes, although this increment started before in 
males than in females, and Bcrp expression showed opposite response in both sexes, decreasing 
in males and increasing in females. Another important difference between both sexes is the 
significant downregulation of Oatp1 transporter only in males after 21 days of treatment. 
  
 
Figure 6. Transporter expression changes in kidney samples obtained from male and female F344 
rats treated with a daily oral dose of vehicle (NaHCO3) or OTA (0.50 mg/kg bw) for 7 or 21 days. 
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For each sex and timepoint, its own control group has been used as calibrator group (1 AU mRNA, shown 
as a black line). Within each sex, gene expression of each transporter after 7 or 21 days of OTA treatment 
was compared to its control. Expression changes were considered statistically significant (*) when p-
value < 0.05 (Mann-Whitney U test). AU: arbitrary units of mRNA level.
 
Figure 7 (modified from Pastor et al., 2016). Illustration of the differential gene expression of the 
kidney transporters evaluated. The figure shows the localization and direction of transport of each 
kidney transporter. Each transporter family is represented with a different color: Slc22 (Oat1, Oat2, Oat3, 
Oat5 and Oat8), Abc (Mrp2, Mrp4 and Bcrp), Slco1 (Oatp1,Oatp2) and Slc15 (Pept1 and Pept2). The 
dimension of the circle illustrates the relative mRNA levels shown in figures 5 and 6. A) Basal males 
(selected as reference for the comparisons). B) Males treated with OTA (0.5 mg/kg) bw for 21 days 
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(changes are relative to A). C) Basal females (changes are relative to A). D) Females treated with OTA 
(0.5 mg/kg) bw for 21 days (changes are relative to C).  
 
4. Discussion 
The objective of this study was to unravel some molecular mechanisms that may underlay the 
different response to OTA toxic insult that has been described in male and female rats. To this 
aim, F344 rats aged 11 weeks at arrival were selected in order to have sexually mature male and 
female animals during the study, and they were orally administered with OTA for one or three 
weeks. The present study was designed to reproduce a study previously published (Arbillaga et 
al., 2008) carried out only in male F344 rats. In the aforementioned study, OTA (0.5 mg/kg bw) 
was administered to animals for 7 and 21 days. This dose was selected as it is slightly higher 
than the one used in several carcinogenicity studies (Castegnaro et al., 1998; Pfohl-Leskowicz 
et al. 1998; Mantle et al., 2005; Son et al., 2003). In this experiment, the same experimental 
design but including female rats was used. Moreover, a lower dose (0.21 mg/kg bw) was 
included at the longer exposure time (21 days) to gain more insights at histopathological level. 
This dose was selected as it was the highest dose tested in the carcinogenicity study carried out 
by the NTP (NTP, 1989).  
Our results showed mild toxic effects in both sexes that were more pronounced in male rats than 
in female rats. In terms of general toxicity, a significant decrease of body weight was observed 
in males, after 14 days of treatment with the highest dose. The presence of blood cells in urine 
and a slight proteinuria, indicative of kidney damage, were also more pronounced in males than 
in females treated with the highest dose. Regarding histopathology, kidney degenerative lesions, 
mainly in proximal tubules, were determined in a time-dependent manner in both sexes but a 
different pattern has been observed: after 7 days of treatment with 0.50 mg/kg bw, the number 
of animals with glomerulonephritis, tubulonephrosis or alterations in the collecting duct was 
higher in the male group than in the female one. Moreover, the intensity of the lesions was also 
higher in males than in females. But after 21 days of treatment, sex differences had disappeared. 
Other authors have also found kidney toxicity in male rats of different strains (Wistar, F344, 
Sprague Dawley), with short-term treatments (2-4 weeks) of 0.20-0.50 mg OTA/kg bw (Abdu et 
al., 2011; Arbillaga et al., 2008; Cariddi et al., 2016; Ciarcia et al., 2016, Dortant et al., 2001; 
El-Haleem et al., 2016; Malekinejad et al., 2011; Palabiyik et al., 2013; Taniai et al., 2012; 
Rached et al., 2008). Rached et al., 2007 determined a No Observed Adverse Effect Level 
(NOAEL) of 0.021 mg/kg bw after a 13-week study in male F344 rats. But, apart from the 
carcinogenic life-span studies carried out with F344 rats (Boorman et al., 1992, NTP, 1989) or 
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with the Dark-Agouti and Lewis strains (Castegnaro et al., 1998, Son et al., 2003), very few 
studies have been performed with rats of both sexes. In weaning Wistar rats fed with an OTA 
contaminated diet (5 ppm) during 90 days, Munro et al. (1974) did not found differences in the 
OTA toxicity that could be related to sex. In male and female F344 rats administered with 1 mg 
OTA/kg bw for 7 consecutive days, Rasonyi et al. (1999) found several kidney lesions that were 
similar in appearance and location in both sexes but more frequent and severe in males than in 
females. In this study, the characteristic OTA-induced karyomegalic cells have been observed in 
both sexes after 21 days of treatment. This in agreement with Boorman et al. (1992) and the 
NTP study (1989) where karyomegaly could be observed with the same incidence in both sexes. 
As expected, mycotoxin administration resulted in a time- and dose-dependent increase of OTA 
in plasma, kidney, and liver of male and female rats. In addition, a clear correlation between 
plasma and tissues concentration was observed, being the OTA plasma concentration 
approximately 10-fold the concentration found in liver and kidney, which were very similar 
between them. This is in agreement with previous dose-repeated toxicity studies carried out in 
male F344 rats orally administered with OTA for 6-21 days (Abbas et al., 2013, Arbillaga et al., 
2008). Regarding sex differences in OTA accumulation, they could only be weakly detected in 
plasma and liver after 7 days of administration. However, after a long exposure, no significant 
differences between males and females could be identified in any matrix.  This is in agreement 
with Tozlovanu et al. (2012) who did not find differences in OTA concentrations between sexes 
in kidney and liver of male and female Dark-Agouti rats consuming OTA contaminated wheat 
for 28 days, and with the predictions of the kinetic model developed by Vettorazzi et al. (2009; 
2010) . However, Mor et al. (2014) in a longer study (24 weeks) found higher levels of OTA in 
plasma, kidney and liver in females than in males.  
The expression of four different transporter families was studied in terms of mRNA levels. 
Firstly, basal levels were analyzed in control animals (Figure 7A and 7C). Sex differences in 
Oat2 (M<F), Oat5 (M<F), Bcrp (M>F) and Oatp1 (M>F) transporters were observed. The 
strongest differences were found in the apical transporter Oat2, with mRNA level 8- or 9-fold 
higher in females than in males. Oatp1 and Bcrp mRNA levels were higher in males with no 
expression of the former in females. These are the most consistent findings and confirm 
previous results in F344 rats (Kwekel et al., 2013, Pastor et al., 2016).  
The expression of transporters was also studied after repeated administration of 0.50 mg/kg bw 
for 7 or 21 days (Figure 7). To our knowledge, this is the first study analyzing gene expression 
modulation of OTA transporters in animals of different sexes after repeated treatment. In 
agreement with our results, some toxicogenomic studies have demonstrated a predominant 
downregulation of kidney transporters in male F344 rats treated for 7 and 21 days at similar 
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doses: 0.30 mg/kg (Marin-Kuan et al., 2006) or 0.50 mg/kg (Arbillaga et al., 2008). Both 
studies confirmed Oat1 (Slc22a6) and Oatp1 (Slco1a1) downregulation. Arbillaga et al. (2008) 
also determined a decreased expression of Oat2 (Slc22a7), Oat5 (Slc22a9), Oat8 (Slc22a19) and 
Pept2 (Slc15a2) after 21 days. Similarly, in male Wistar rats treated with 0.50 mg/kg bw for 10 
days, Zlender et al. (2009) found a downregulation of Oat1, Oat2, Oat3 and Oat5. Regarding 
Mrp2 expression, our results showed an increase of its mRNA level in both sexes after 21 days. 
In male F344 rats under similar conditions, a decrease in mRNA level was found by Arbillaga et 
al. (2008) and Marin-Kuan et al. (2006) but in Elker male rats treated with 0.21 mg/kg bw after 
1, 3, 7 and 14 days, Stemmer et al. (2007) also found an increase in Mrp2 expression, in 
agreement with our results. 
Overall, our results support the fact that OTA modulates the gene expression of different renal 
proteins involved in its transport. Indeed, our study shows, for the first time, that OTA 
modulation shows important sex-dependent differences (figure 6). Some of the most important 
distinctive aspects are related with a different direction of modulation in each sex (Bcrp), 
absence of modulation in one sex but downregulation in the other (Oat3) or absence of basal 
expression in one sex (figure 5)  but high modulation by OTA in the other sex (such as Oatp1).  
 
Moreover, changes in expression of the different transporters do not appear at the same 
timepoint in each sex. This influence of the time of OTA exposure appears to be especially 
important for Oat transporters. In females, the Oat downregulation observed after 21 days was 
already observed at 7 days; while in males the strong downregulation found at 21 days was not 
present after 7 days (except for Oat1). The different effect of time in each sex, can also be also 
observed in a study carried out after a single oral dose of OTA (0.5 mg/kg bw), where an 
increase in the expression of some Oat transporters (mainly Oat2) was observed in male rats 
after 24h of OTA exposure, while in females, downregulation was already the predominant 
effect since the beginning (Pastor et al., 2016). In another study carried out in Wistar male rats 
(Zlender et al., 2009) a dual effect in Oat gene expression was observed depending on the dose 
administered (upregulation at low doses, down regulation at high dose). Thus, time- and dose- 
dependent effects appear to be crucial for the correct interpretation of sex differences at kidney 
transporter level after OTA exposure.  
However, despite the gene expression sex differences observed in the kidney transporters at 
individual level, it is difficult to conclude how the final balance (figure 7) would influence OTA 
toxicokinetics in both sexes, but it does not seem to support a higher accumulation of OTA in 
male rats as proposed by Mally (2012). Indeed, this is in accordance with the similar OTA 
levels measured in the kidney in males and females (figure 4). 
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On the other hand, and as many kidney transporters are regulated by sex hormones, hormone 
levels were quantified in the present study, A clear dose- and time-dependent decrease of 
progesterone was determined in females. Progesterone and testosterone, in males, and estradiol, 
in females, were weakly increased after 21 days. T3 and T4 levels were not modified in any sex 
after mycotoxin administration. The role of OTA as endocrine disruptor has been slightly 
studied and the whole range of experimental systems, doses or time of exposure make hard to 
draw a conclusion about mycotoxin-induced effect on hormone regulation. In agreement with 
our results, an in vitro study using the JEG-3 cell line (human placenta cells), determined an 
increase dose- and time-dependent of progesterone production (Woo et al., 2013). Frizzell et al. 
(2013) using H295R cell line as steroidogenesis model, showed an increase of estradiol 
production, but no effect in testosterone and progesterone levels. Regarding in vivo studies, 
testosterone level increased in testis of male Wistar rats, after 3 weeks of OTA treatment (289 
µg/kg bw each 48 h) (Gharbi et al., 1993). However, Kumar et al. (2011) and Hassan et al. 
(2010) observed a testosterone reduction after 1 or 6 months of administration of 4 or 1 ppm 
OTA in feed, respectively. Finally, Mor et al. (2014), observed no changes in testosterone level 
in 16-week-old male rats that were fed with 20 g of contaminated diet (5 mg/kg in feed) for 24 
weeks.  
Regarding transporter regulation by hormones, our results indicate that progesterone might be 
involved in OTA-induced changes. As mentioned before, this hormone increases Oat1, Oat2 
and Oat5, does not affect Oat3 and diminishes Bcrp and Pept1 expressions (Breljak et al., 2010, 
Ljubojevic et al., 2004, Ljubojevic et al., 2007, Watanabe et al., 2006, Wu et al., 2013). In 
agreement with this, the decrease of Oat1, Oat2, Oat5, the increase of Bcrp and Pept1 (no 
statistically significant) and the no effect on Oat3 expression observed in females is correlated 
with the progesterone decrease. With respect to the males, they have lower basal progesterone 
levels than females and only a tendency to its increase was observed after OTA treatment 
together with a slight tendency to testosterone increase. Therefore, it is difficult to correlate the 
variation in both hormone levels with the effect in transport expression in males. 
In conclusion, after 7 days of treatment, histopathological findings were indicative of a more 
pronounced effect in male kidneys than in female ones with a tendency to be equal in both sexes 
over time. No significant differences in plasma, liver or kidney OTA concentrations were found 
between both sexes, with a plasma concentration that was approximately ten fold higher than 
liver and kidney concentrations at both time points. Analysing individual transporter expression, 
sex differences were determined both at basal level and after OTA treatment. Downregulation 
was the general OTA-induced effect. Oats response was slower in males than females and Oat3 
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did not show any expression change in females. Oatp1 was solely and strongly downregulated 
in males after 21 days. Finally, an opposite effect was observed in Bcrp after 21 days: its 
expression decreased in males but increased in females. Moreover, a progesterone dose- and 
time-dependent decrease was observed in females, and it might be involved in Oats, Bcrp and 
Pept1 regulation. Overall, our results indicate that 1) OTA treatment modulates kidney 
transporters gene expression in a sex-dependent manner; 2) the influence of the time of OTA 
exposure in each sex seems crucial when evaluating kidney transporters in both sexes and 3) 
despite the sex-differences observed, the final balance of the influence of the different 
transporters gene expression in OTA toxicokinetics at renal cell level, does not seem to support 
a higher accumulation of OTA in male kidneys.  
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Supplementary data 
Table 1 supplementary data. Individual body weights (g) of all the animals on day of arrival. 
Body weights (g) on day of arrival 
    FEMALES MALES 
    7 DAYS 21 DAYS 7 DAYS 21 DAYS 
Control 
1 156.0 155.2 260.9 262.4 
2 159.3 163.3 249.0 268.3 
3 156.9 158.2 269.4 262.3 
4 163.3 168.4 275.4 271.3 
5 147.0 164.19 284.6 264.5 
6 161.4 145.2 266.7 243.5 
0.21 mg/kg  
1 
 
157.0 
 
272.9 
2 
 
144.2 
 
245.7 
3 
 
147.9 
 
257.2 
4 
 
169.3 
 
264.0 
5 
 
169.6 
 
267.0 
6   163.4   265.7 
0.5 mg/kg  
1 162.4 158.9 258.5 239.3 
2 156.2 145.5 268.3 223.7 
3 146.6 154.7 257.8 251.9 
4 174.1 142.0 257.8 264.8 
5 155.7 163.6 271.5 266.6 
6 160.2 169.4 254.7 262.3 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
Table 2 supplementary data. Blood biochemistry. Results are shown as mean ± standard deviation.  
  
  
Dose (mg/kg bw) 
Sex Males Females 
Parameter Time (days) 0 0.21 0.5 0 0.21 0.5 
Albumine 
(g/dL) 
7 4.10 ± 0.30   4.413 ± 0.15 4.59 ± 0.52   4.53 ± 0.15 
21 4.34 ± 0.35 4.52 ± 0.29 4.71 ± 0.24 5.00 ± 0.68 4.16 ± 0.58 4.63 ± 0.14 
Total bilirubin 
(mg/dL) 
7 0.04 ± 0.03 
 
0.06 ± 0.02 0.11 ± 0.04 
 
0.10 ± 0.05 
21 0. 07 ± 0.04 0.07 ± 0.04 0.09 ± 0.05 0.18 ± 0.15 0.10 ± 0.04 0.16 ± 0.08 
Glucose 
(mg/dL) 
7 104.67 ± 13.94   114.33 ± 6.15 107.80 ± 17.47   89.00 ± 6.96 
21 112.40 ± 42.90 101.50 ± 11.62 105.83 ± 10.09 82.67 ± 10.54 78.00 ± 13.40 71.00 ± 15.19 
Cholesterol 
(mg/dL) 
7 55.67 ± 8.94 
 
46.00 ± 6.75 78.80 ± 13.55 
 
60.17 ± 9.39 
21 64. 40 ± 9.26 51.67 ± 5.43 52.83 ± 6.40 107.83 ± 18.65 72.60 ± 16.70 71.33 ± 15.24 
Urea 
(mg/dL) 
7 42.83 ± 2.86   43.67 ± 6.74 44.75 ± 10.24   52.67 ± 11.88 
21 43.80 ± 11.23 46.00 ± 3.22 53.67 ± 2.25 54.50 ± 2.12 45.25 ± 10.47 51.5 ± 3.51 
AST             
(U/I) 
7 202.17 ± 43.62 
 
170.67 ± 29.04 277.50 ± 63.51 
 
259.50 ± 57.37 
21 190.00 ± 28.18 260.00 ± 119.26 240.50 ± 73.70 369.00 ± 118.79 293.00 ± 51.68 263.75 ± 52.91 
ALT                        
(U/I) 
7 48.33 ± 4.50   31.83 ± 6.43 36.50 ± 5.45   26.50 ± 4.95 
21 36.75 ± 13.20 44.00 ± 9.57 42.00 ± 7.64 - - - 
Total protein 
(g/dL) 
7 6.87 ± 0.63 
 
6.92 ± 0.23 7.16 ± 0.43 
 
5.65 ± 2.58 
21 5.66 ± 3.07 7.27 ± 0.50 7.62 ± 0.46 7.98 ± 0.98 6.96 ± 0.38 7.02 ± 0.44 
Creatinine 
(mg/dL) 
7 0.70 ± 0.07   0.75 ± 0.12 0.82 ± 0.09   0.78 ± 0.09 
21 0.86 ± 0.09 0.90 ± 0.07 0.93 ± 0.14 0.82 ± 0.34 0.83 ± 0.09 0.97 ± 0.09 
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Table 3 supplementary data.  Validation results of the linearity study. Two calibration curves 
of six data points each were plotted in the ranges of 2 – 20 and 20 – 200 µg/L. Three replicates 
of calibrations standards were analysed for each point on 1 day (within-day) and on 3 days 
(between-day). 
Range (µg/L) 2 - 20  20 - 200 
Curve equationa y= 6.63x - 2.42 y= 6.68x - 7.82 
r2 b 0.999 0.999 
Slope limits (p= 
95%) 6.27; 6.99 6.61; 6.75 
RSDc of response 
factors (%) 3.61 1.23 
  Within-day variability (n= 3) Between-day variability (n= 9) 
Concentration 
(µg/L) 
Detected 
mean value 
(µg/L) 
RSDc 
(%) 
Ad 
(%) 
Detected 
meanvalue 
(µg/L) 
RSDc 
(%) 
Ad 
(%) 
Range 2 – 20 (µg/L) 
  2 2.14 0.14 6.84 2.15 1.56 7.53 
  6 5.85 0.96 2.42 5.78 3.69 3.66 
  20 20.21 0.73 1.04 20.48 2.20 2.39 
Range 20 – 200 (µg/L) 
  20 20.86 0.70 4.31 21.13 2.11 5.64 
  60 58.80 1.38 1.99 58.76 3.08 2.07 
  200 199.38 1.41 0.31 200.48 1.66 0.24 
a
 y: peak area x: concentration of OTA (µg/L). b Correlation coefficient. c Relative standard deviation.d 
Accuracy or standard error of the estimate (SE). 
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Table 4 supplementary data. Recovery study results. The repeatability and reproducibility of 
this process was studied by carrying out the complete recovery experiment for each matrix on 
1 day (within-day) and on 3 or 4 different days (between-day). 
 
OTA 
concentration 
(µg/L or 
µg/kg) 
Recovery 
(%) RSD
a
 (%) 
Global 
recovery 
(%) 
RSDa (%) 
Plasma 
Within-day n= 3 n= 3 n= 9 n= 9 
8.40 98.89 3.21 
95.52 4.16 56.00 95.95 1.23 
559.90 91.71 3.96 
Between-day 
(3 days) n= 9 n= 9 n= 27 n= 27 
8.40 96.46 4.76 
94.14 4.14 56.00 92.56 3.55 
559.90 93.39 3.02 
Kidney 
Within-day n= 3 n= 3 n= 9 n= 9 
56 102.14 1.47 
96.75 4.95 224 96.79 1.03 
2239.7 91.33 1.15 
Between-day 
(4 days) n= 12 n= 12 n= 36 n= 36 
56.00 101.00 5.09 
96.79 4.80 224.00 96.63 1.27 
2239.70 92.76 2.10 
Liver 
Within-day n= 3 n= 3 n= 9 n= 9 
56.00 97.73 2.52 
94.42 3.59 224.00 94.39 2.79 
2239.70 91.14 0.61 
Between-day 
(4 days) n= 12 n= 12 n= 36 n= 36 
56.00 102.43 3.48 
95.59 6.47 224.00 95.34 2.17 
2239.70 89.00 2.83 
a Relative standard deviation. 
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Table 5 supplementary data. Means and standard deviations of ochratoxin A levels in plasma 
and tissues. For comparison with other studies, data are shown in duplicate but with different 
units (µg/L or µg/kg) and on a molar basis.   
 
A 
     
Time (days) 
Treatment 
(mg/kg bw) 
Sex 
Plasma Kidney Liver 
(µg/L) (µg/kg) (µg/kg) 
7 0.50 
M 7610.31 ± 734.98  535.67 ± 44.23  749.22 ± 61.83  
F 8831.79 ± 539.49 609.12 ± 46.48  839.47 ± 50.28  
21 
0.21 
M 9011.80 ± 560.83  748.96 ± 141.39  909.88 ± 86.11  
F 8643.60 ± 751.30  661.07 ± 96.06  845.79 ± 54.18  
0.50 
M 17914.26 ± 1125.75  1407.17 ± 206.42  1776.02 ± 131.24  
F 17003.95 ± 1014.83  1345.37 ± 71.74  1646.31 ± 242.48  
B 
     
Time (days) 
Treatment 
(mg/kg bw) 
Sex 
Plasma Kidney Liver 
(nmol/mL) (pmol/g) (pmol/g) 
7 0.50 
M 18.85 ± 1.82 1326.54 ± 109.53 1855.38 ± 153.12 
F 21.87 ± 1.34 1508.43 ± 115.10 2078.87 ± 124.51 
21 
0.21 
M 22.32 ± 1.39 1854.73 ± 350.14 2253.24 ± 213.24 
F 21.41 ± 1.86 1637.08 ± 237.88 2094.52 ± 134.17 
0.50 
M 44.36 ± 2.79 3484.73 ± 511.18 4398.16 ± 325.00 
F 42.11 ± 2.51 3331.69 ± 177.66 4076.94 ± 600.48 
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Highlights 
1- Ochratoxin A levels in plasma, kidney and liver are similar between both sexes in F344 rats 
after 7 and 21 days of exposure. 
2. At 7 days, kidney histopathology showed higher toxicity in males but tended to equalize with 
females over time. 
3. Downregulation of kidney transporters gene expression was the general OTA-induced effect. 
4. Oats´ response was slow and Oatp1 and Bcrp were inhibited in males; in females Oat3 was 
not affected but Bcrp was upregulated. 
5. Females showed a dose- and time-dependent decrease of progesterone that might be involved 
in kidney transporters expression. 
